Search results

Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

Result type

Technology appraisal guidance

Published

25 August 2010

Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

22 September 2010

NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.

Result type

Technology appraisal guidance

Published

27 October 2010

NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.

Result type

Technology appraisal guidance

Published

27 October 2010

Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

Result type

Technology appraisal guidance

Published

18 January 2023

Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

Result type

Technology appraisal guidance

Published

8 February 2023

Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.

Result type

Technology appraisal guidance

Published

15 February 2023

Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

Result type

Technology appraisal guidance

Published

22 February 2023

Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

Result type

Technology appraisal guidance

Published

1 March 2023

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

Result type

Technology appraisal guidance

Published

28 February 2023

NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.

Result type

Technology appraisal guidance

Published

27 July 2022